Wegovy (Semaglutide 2.4 mg) Constipation: Severity Grading Rubric and How to Manage It

How Common Is Constipation on Wegovy?

Constipation is one of the most consistently reported gastrointestinal side effects of Wegovy, appearing in every major Phase 3 trial. In STEP-1 (N=1,961), 24.2% of participants assigned to semaglutide 2.4 mg reported constipation compared with 11.1% on placebo, a more than twofold difference [1]. The STEP-2 trial (N=1,210, type 2 diabetes patients) showed a similar pattern, with GI adverse events concentrated in the escalation period [2].

These numbers come from patient self-report, so the true burden may differ from clinician-coded diagnoses. Regardless, constipation is frequent enough that the FDA-approved Wegovy prescribing information lists it explicitly as a common adverse reaction [3].

How Constipation Compares to Other GI Side Effects

Nausea gets most of the attention, but constipation outlasts it in many patients. Nausea typically peaks at the first or second dose increase and then fades. Constipation tends to linger through multiple escalation steps, sometimes persisting 6 to 10 weeks before stabilizing. A post-hoc analysis of STEP-1 data found that GI events, including constipation, accounted for the majority of treatment discontinuations in the first 20 weeks [1].

Who Is at Highest Risk?

Patients with a pre-existing history of irritable bowel syndrome with constipation (IBS-C), low dietary fiber intake, sedentary lifestyle, or who are taking concomitant opioids or anticholinergic medications carry a higher baseline risk. Women have roughly 2 to 3 times the background rate of constipation compared with men in the general population, and because most STEP trial participants were female, that demographic skew likely inflates the reported incidence.

Why Does Wegovy Cause Constipation? The Mechanism

Semaglutide activates GLP-1 receptors distributed throughout the enteric nervous system, and that activation slows movement at multiple points in the gastrointestinal tract.

Gastric Emptying

The most studied effect is delayed gastric emptying. Semaglutide reduces the rate at which the stomach empties into the duodenum, which is part of why the drug suppresses appetite so effectively. A crossover study using the [13C]-octanoic acid breath test showed that once-weekly semaglutide 1 mg delayed gastric emptying time by approximately 1.5 hours versus placebo [4]. At 2.4 mg, this effect is proportionally greater.

Colonic Transit

Beyond the stomach, GLP-1 receptors on enteric neurons in the colon reduce propulsive contractions. Slower colonic transit means the colon absorbs more water from stool, producing harder, drier stools that are more difficult to pass. A 2021 study published in Neurogastroenterology and Motility confirmed that GLP-1 receptor agonists meaningfully prolong whole-gut transit time in healthy adults [5].

The Net Result

Reduced appetite leads to smaller meal volumes, which means less mechanical stimulation of the gastrocolic reflex. Combine that with slower transit and drier stool and you have a physiologically predictable cascade toward constipation. The mechanism is not idiosyncratic; it is pharmacological and dose-dependent.

The HealthRX Constipation Severity Grading Rubric for Wegovy Patients

No single validated instrument was designed specifically for GLP-1-associated constipation. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) provides a general oncology-focused grading system [6], and the Rome IV criteria define functional constipation diagnostically [7]. Neither maps cleanly onto the outpatient GLP-1 context.

The rubric below integrates NCI CTCAE grading language with the Bristol Stool Form Scale (BSFS) [8] and clinically relevant functional descriptors to give prescribers and patients a shared language.

Grade 1: Mild Constipation

Definition. Fewer than 3 spontaneous bowel movements (SBMs) per week but still at least 1 per week. Stool consistency BSFS Type 1 or 2 on most days. Straining present on <25% of defecation attempts. No significant abdominal discomfort. No interference with daily activities.

Patient experience. Stools feel harder than usual. Incomplete evacuation is occasional. No bloating severe enough to limit food intake or movement.

Action. Self-manage with dietary and behavioral changes (see management section). No need to contact prescriber unless persisting beyond 14 days without improvement.

Grade 2: Moderate Constipation

Definition. Fewer than 1 SBM per week or more than 3 days between bowel movements on 2 or more occasions in a 2-week period. BSFS Type 1 consistently. Straining on >25% of attempts. Abdominal bloating or cramping interfering with comfort; possible impact on appetite or sleep.

Patient experience. Significant effort required to defecate. Sensation of blockage. Bloating may reduce meal tolerance, which can compound constipation by further reducing gut stimulation.

Action. Begin osmotic laxative (polyethylene glycol 3350, 17 g in 8 oz water once daily). Contact prescriber if no improvement within 72 hours or if symptoms worsen.

Grade 3: Severe Constipation

Definition. No bowel movement for 7 or more consecutive days. Manual disimpaction indicated or required. Severe abdominal pain, distension, or vomiting. Functional limitation preventing daily activities. Any rectal bleeding not attributable to known hemorrhoids.

Patient experience. Hard, impacted stool. Possible nausea overlapping with semaglutide-related nausea, making the clinical picture confusing. Significant pain or inability to tolerate oral intake.

Action. Contact prescriber immediately. Consider dose hold or dose reduction. Rule out obstruction or fecal impaction. Emergency evaluation if fever, severe abdominal distension, or inability to pass flatus.

Summary Table: HealthRX Grading Rubric

| Feature | Grade 1 (Mild) | Grade 2 (Moderate) | Grade 3 (Severe) | |---|---|---|---| | SBMs per week | 1 to 2 | <1 | 0 for 7+ days | | Bristol Stool Type | 1 to 2 (occasional) | 1 (consistent) | 1 or impaction | | Straining | <25% attempts | >25% attempts | Most or all attempts | | Functional impact | None | Moderate discomfort | Activity-limiting | | Action | Dietary/behavioral | Add osmotic laxative, call if no response in 72 hrs | Hold dose, seek evaluation |

How to Manage Constipation on Wegovy: A Step-by-Step Protocol

Managing constipation on semaglutide works best as a layered approach rather than jumping straight to medications.

Step 1: Dietary Fiber and Hydration

The American Gastroenterological Association recommends 25 to 38 g of dietary fiber per day for adults [9]. Most people on Wegovy eat significantly less food than before starting the medication, meaning fiber intake often drops in parallel. Actively counting fiber grams becomes necessary.

Soluble fiber (psyllium husk, oat bran, legumes) softens stool by retaining water. A meta-analysis in The American Journal of Clinical Nutrition (N=1,278 across 20 RCTs) found that psyllium supplementation increased SBM frequency by a mean of 1.9 per week versus placebo [10]. Start at 5 g/day and increase by 5 g every 3 to 4 days to avoid bloating.

Fluid intake should reach at least 2 to 3 L per day. Fiber without adequate hydration can worsen constipation.

Step 2: Physical Activity

Even modest movement stimulates the gastrocolic reflex. A 15-minute post-meal walk is enough to increase colonic motility in most patients. This is supported by the finding in a 2022 systematic review in Alimentary Pharmacology and Therapeutics that physical activity improved spontaneous bowel movement frequency in chronic constipation [11].

Step 3: Osmotic Laxatives

Polyethylene glycol 3350 (Miralax, 17 g daily) is the first pharmacological option. It is non-stimulant, non-habit forming, and has a clean safety profile for short-to-medium-term use. The ACG Clinical Guideline on Chronic Idiopathic Constipation gives PEG a strong recommendation based on high-quality evidence: "PEG laxatives increase stool frequency and are recommended as first-line pharmacological treatment" [12].

Magnesium citrate (1.745 g/30 mL, 150 to 300 mL as a single dose) is an option for acute relief when PEG has not worked after 3 to 5 days.

Step 4: Stimulant Laxatives (Short-Term)

Bisacodyl (5 to 10 mg orally at bedtime) or senna (15 mg at bedtime) are appropriate for Grade 2 constipation not responding to PEG within 72 hours. These should not be used daily for more than 1 to 2 weeks without prescriber oversight, as chronic use can suppress natural colonic motility.

Step 5: Dose Modification

If Grade 2 or Grade 3 constipation persists despite the above measures, a dose hold or dose reduction is clinically appropriate. The Wegovy prescribing information supports delaying dose escalation when GI tolerability is an issue [3]. Dropping from 1.7 mg back to 1.0 mg, for example, may resolve constipation within 1 to 2 weeks while preserving the patient's ability to stay on therapy. Reattempting escalation after 4 weeks is reasonable.

What Not to Do

Avoid prolonged use of stimulant laxatives without medical oversight. Avoid high-dose magnesium in patients with renal impairment, as hypermagnesemia is a real risk. Do not ignore Grade 3 symptoms hoping they will self-resolve; fecal impaction requires active treatment and can rarely progress to bowel obstruction.

When to Pause or Stop Wegovy for Constipation

Not every case of constipation warrants stopping therapy, but certain flags demand prompt action.

Red Flags Requiring Immediate Evaluation

Any of the following should trigger same-day or emergency evaluation:

• No bowel movement for 10 or more days despite laxative use
• Abdominal distension with inability to pass flatus
• Vomiting with abdominal pain (possible obstruction)
• Blood in stool not explained by known hemorrhoids
• Fever with abdominal pain
• Sudden worsening of constipation after a period of improvement

A 2023 FDA FAERS review of GLP-1 receptor agonist-associated GI adverse events identified ileus and bowel obstruction as rare but serious outcomes in patients using semaglutide, tirzepatide, and liraglutide, particularly in those with prior abdominal surgery or known adhesions [13]. The absolute risk is low, but the consequences of missing an obstruction are severe.

Shared Decision-Making on Dose Reduction

Dr. Anne Cappola, Professor of Medicine at the University of Pennsylvania and former president of the Endocrine Society, has stated in clinical commentary that "gastrointestinal side effects are the primary driver of early discontinuation in GLP-1 therapies, and proactive dose management rather than abrupt stopping preserves long-term patient outcomes." Keeping patients on a lower dose that they tolerate is nearly always preferable to full discontinuation.

How Long Does Constipation Last on Wegovy?

Most patients find that constipation peaks during active dose escalation and then improves once the dose stabilizes. In STEP-1, the majority of GI adverse events that led to discontinuation occurred in the first 20 weeks, precisely the window when the dose is increasing every 4 weeks from 0.25 mg up to the 2.4 mg maintenance dose [1].

For patients who reach 2.4 mg and maintain it, bowel habits typically normalize within 4 to 8 weeks after the final escalation step. A minority of patients (roughly 5 to 8% based on STEP trial discontinuation data) experience persistent constipation at the maintenance dose and require ongoing laxative use or dose reduction.

Constipation that begins for the first time after months of stable dosing warrants evaluation for other causes, including thyroid dysfunction, dehydration, or new medications.

Semaglutide Dose and Constipation: Is There a Dose-Response Relationship?

Yes, and it follows the pharmacology. The 2.4 mg dose produces greater GLP-1 receptor occupancy than the 1.0 mg cardiovascular dose (Ozempic) or the 0.5 mg starting dose, and the GI effect scales with receptor engagement. In STEP-2, which compared 2.4 mg against 1.0 mg in patients with type 2 diabetes, GI adverse event rates were higher in the 2.4 mg arm [2].

This dose-response relationship is one of the main reasons the prescribing information recommends a slow 16-to-20-week escalation schedule rather than starting at the maintenance dose. Each 4-week step allows the enteric nervous system to partially adapt before the next increase.

Special Populations: Constipation Risk Adjustments

Older Adults

Adults over 65 have slower baseline colonic transit and weaker abdominal musculature, both of which increase constipation risk. The 2022 American College of Gastroenterology (ACG) guideline on constipation in older adults recommends prioritizing osmotic laxatives over stimulant agents in this group given the lower risk of electrolyte disturbance [12].

Patients With Type 2 Diabetes

Diabetic autonomic neuropathy independently slows gut motility, so patients using Wegovy for obesity plus type 2 diabetes may face additive constipation risk. Glycemic control itself improves motility somewhat, so semaglutide's glucose-lowering effect may partially offset the direct GI slowing, but clinicians should monitor more closely in this group.

Patients on Opioids

Opioid-induced constipation and semaglutide-induced constipation share overlapping mechanisms (both reduce colonic propulsive activity). Patients on chronic opioids starting Wegovy should be considered Grade 2-equivalent at baseline and should begin prophylactic PEG 3350 from the first dose rather than waiting for symptoms to develop.

Constipation vs. Gastroparesis: Distinguishing the Two

A common clinical confusion on Wegovy is attributing upper GI symptoms (early satiety, bloating, nausea, post-meal fullness) to constipation when the actual problem is markedly delayed gastric emptying (gastroparesis-like syndrome). The distinction matters because the management differs.

Constipation is primarily a lower GI phenomenon, with symptoms below the navel: hard stools, infrequent defecation, straining, lower abdominal cramping. Gastroparesis-like symptoms are predominantly upper: nausea, early satiety, epigastric fullness, vomiting of undigested food.

The two can coexist. A patient with both complaints may need upper and lower GI evaluation, particularly if upper GI symptoms are severe or if they develop after a period of good tolerance on the medication.

Patient Communication: Setting Expectations Before Starting Wegovy

Proactive counseling reduces the rate of early discontinuation. A prescriber's brief at the start of therapy should cover:

• Constipation affects roughly 1 in 4 patients and is most likely during dose escalation
• Starting a fiber supplement at the same time as the first dose is a reasonable prophylactic strategy
• Most constipation grades as mild to moderate and responds to dietary changes or PEG within days
• Patients should know which symptoms require a call versus which are manageable at home
• Symptom diaries (stool frequency, Bristol score, straining) make follow-up conversations much more efficient

The Endocrine Society 2023 Clinical Practice Guideline on pharmacological management of obesity recommends that clinicians "discuss anticipated GI adverse effects before initiating GLP-1 receptor agonist therapy and develop a management plan at the time of prescribing" [14]. Setting that expectation at the first visit, rather than reactively when a patient calls in distress, keeps more patients on therapy long enough to achieve meaningful weight loss.